AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29661560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid heparan sulfate measurements
Number of subjects: 19
Study 29661699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97 mg/103 mg twice daily)
Number of subjects: 3784
Study 29661699 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 3784
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Women consuming 50 to 250 calories more on weekend days than on Mondays
Number of subjects: 7007
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with balanced consumption (±50 calories)
Number of subjects: 7007
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Women consuming 250 to 500 calories more on Mondays than on weekend days
Number of subjects: 7007
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Women consuming more than 500 calories more on Mondays than on weekend days
Number of subjects: 7007
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Men consuming 250 to 500 calories more on Mondays than on weekend days
Number of subjects: 7007
Study 29661750 — intervention group
Group type: EXPERIMENTAL
Intervention: Men consuming more than 500 calories more on Mondays than on weekend days
Number of subjects: 7007
Study 29661775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, Dexamethasone, and Rituximab
Number of subjects: 0
Study 29661781 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 80
Study 29661781 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 80
Study 29661934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption
Number of subjects: 61364
Study 29662686 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class 1 (60.9% of participants) - primarily reported domestic-focused activities; lowest caloric expenditure.
Number of subjects: 115
Study 29662686 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class 2 (19.5% of participants) - reported domestic-focused activities, leisure-time physical activities, and structured exercise activities.
Number of subjects: 115
Study 29662686 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class 3 (19.6% of participants) - reported domestic-focused activities, leisure-time physical activities, and structured exercise activities; highest caloric expenditure.
Number of subjects: 115
Study 29662875 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based second-line regimen with adherence counseling for 3 months
Number of subjects: 1317
Study 29662875 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence boosting counseling
Number of subjects: 1317
Study 29662875 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype resistance tests
Number of subjects: 1317
Study 29662960 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene discontinuation for 10 days
Number of subjects: 0
Study 29663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing dysfunction (abnormal swallowing capacity)
Number of subjects: 391
Study 29663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of aspiration (cough and voice change)
Number of subjects: 391
Study 29663160 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of undernutrition
Number of subjects: 391
Study 29663330 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging
Number of subjects: 504
Study 29663330 — intervention group
Group type: COMPARATOR
Intervention: Standard operator visual assessment alone
Number of subjects: 504
Study 29663523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0
Study 29663523 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 0
Study 29664050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level perceived stressfulness (HPS) of stressful life events (SLEs)
Number of subjects: 1029
Study 29664050 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by the 17-item Hamilton Depression Scale (HAMD-17)
Number of subjects: 1029
Study 29664672 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care management of sleep apnea, details on dosage and duration not available
Number of subjects: 0
Study 29664672 — intervention group
Group type: COMPARATOR
Intervention: Standard care for sleep apnea, details on dosage and duration not available
Number of subjects: 0
Study 29664709 — intervention group
Group type: EXPERIMENTAL
Intervention: G1XCGD, a lentiviral vector for ex vivo gene therapy
Number of subjects: 0
Study 29665034 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFL (nonalcoholic fatty liver) prevalence assessment
Number of subjects: 503
Study 29665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered glucose homeostasis in adolescents with NAFL
Number of subjects: 503
Study 29665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for NAFL incidence
Number of subjects: 503
Study 29665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for resolution of NAFL at follow-up
Number of subjects: 503
Study 29665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Model predictive performance with gene variants
Number of subjects: 503
Study 29665842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory re-learning in combination with task-specific training
Number of subjects: 0
Study 29665842 — intervention group
Group type: COMPARATOR
Intervention: Task-specific training only (control group)
Number of subjects: 0
Study 29665840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A pretreatment (2.5 mg/kg) in deceased organ donors
Number of subjects: 0
Study 29665840 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 29666047 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 84
Study 29666047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical status
Number of subjects: 84
Study 29666122 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of dexamethasone phosphate (1.2 mA/min at 0.4 mA)
Number of subjects: 18
Study 29666122 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic delivery of dexamethasone phosphate
Number of subjects: 18
Study 29666163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development-III (BSID III) cognitive score cutoff <70
Number of subjects: 2113
Study 29666163 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic examination
Number of subjects: 2113
Study 29666163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 2113
Study 29666296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (20 mg/kg) and Bevacizumab (10 mg/kg) every 2 weeks
Number of subjects: 36
Study 29666297 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of everolimus by mouth (PO) weekly
Number of subjects: 53
Study 29666297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of everolimus PO daily
Number of subjects: 53
Study 29666705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise defined by CPET
Number of subjects: 48
Study 29667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically computed QRS-score from 12-lead ECG
Number of subjects: 1151
Study 29667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically computed QRS-score ≥ 9
Number of subjects: 1151
Study 29667014 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-score ≥ 3
Number of subjects: 1151
Study 29667940 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous nerve block with 10 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 18
Study 29667940 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving 10 mL saline
Number of subjects: 18
Study 29668600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes and genomic, epigenomic, and protein alterations analysis using a panel of 143 known cancer genes (Oncomine Comprehensive Assay).
Number of subjects: 200
Study 29668600 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter methylation analysis for selected genes and tissue microarray for clinically relevant proteins (e.g., PD-L1, Erb-2, VEGFR2).
Number of subjects: 200
Study 29669226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with autologous CD34+ cells transduced with the BB305 vector
Number of subjects: 22
Study 29669226 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 29669391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (a small molecule inhibitor of Syk)
Number of subjects: 450
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative sedation with monitoring using NeuroSense and ANI monitors
Number of subjects: 40
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for pain/comfort assessment by patients (if possible)
Number of subjects: 40
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' assessment of pain, awareness, and communication
Number of subjects: 40
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives' perception of the quality of the dying process
Number of subjects: 40
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational scales by trained investigators
Number of subjects: 40
Study 29669562 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and audio registration
Number of subjects: 40
Study 29669676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex-Border Post-Op (intervention group)
Number of subjects: 209
Study 29669676 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive dressing (Cosmopor) (control group)
Number of subjects: 209
Study 29669701 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice per day (oral) on a continuous daily dosing schedule for 21 days until disease progression, unacceptable toxicity, or patient refusal.
Number of subjects: 20
Study 29669701 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 20
Study 29669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision tool incorporating the US MEC guidelines
Number of subjects: 0
Study 29669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative surveys and semistructured qualitative interviews
Number of subjects: 0
Study 29669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of qualitative data from interviews and field observations
Number of subjects: 0
Study 29669753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg orally daily
Number of subjects: 14
Study 29669753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg orally daily
Number of subjects: 14
Study 29669753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (both doses)
Number of subjects: 14
Study 29669934 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin
Number of subjects: 15
Study 29669934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 15
Study 29669936 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 E7-specific TCR T cell therapy
Number of subjects: 0
Study 29669944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus low density granulocytes (LDGs)
Number of subjects: 0
Study 29669944 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 29669947 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT + CTL019
Number of subjects: 10
Study 29669947 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019
Number of subjects: 10
Study 29670545 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-AGE Diet
Number of subjects: 0
Study 29670545 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29670761 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 325
Study 29670761 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q4W
Number of subjects: 325
Study 29670761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 29671186 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine-Free Cardiac Anesthesia
Number of subjects: 0
Study 29671186 — intervention group
Group type: COMPARATOR
Intervention: Standard benzodiazepine anesthesia
Number of subjects: 0
Study 29671866 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (IHV)
Number of subjects: 31
Study 29671866 — intervention group
Group type: COMPARATOR
Intervention: Control (standard weaning procedure)
Number of subjects: 31
Study 29671921 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 29671921 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29672090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 85
Study 29672210 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast stress echocardiography (CSE)
Number of subjects: 400
Study 29672210 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress electrocardiogram (sECG)
Number of subjects: 400
Study 29672210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest BNP
Number of subjects: 400
Study 29672210 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal sECG
Number of subjects: 400
Study 29672210 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 400
Study 29672676 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 30
Study 29672891 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks
Number of subjects: 100
Study 29673046 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed type 2 diabetes
Number of subjects: 2
Study 29673370 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy (RRT) within 6 hours
Number of subjects: 118
Study 29673370 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of renal replacement therapy (RRT) by urgent indication
Number of subjects: 118
Study 29673370 — intervention group
Group type: EXPERIMENTAL
Intervention: Early RRT
Number of subjects: 118
Study 29673370 — intervention group
Group type: COMPARATOR
Intervention: Standard RRT
Number of subjects: 118
Study 29673379 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU/ml
Number of subjects: 52
Study 29673379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study 29673381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone message group (either text messages [SMS] or voice messages [VM])
Number of subjects: 600
Study 29673381 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly monitoring survey)
Number of subjects: 600
Study 29673798 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO-oximetry
Number of subjects: 0
Study 29673890 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin)
Number of subjects: 210
Study 29673942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick-borne encephalitis (TBE) booster vaccine
Number of subjects: 119
Study 29674306 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABEO telemedicine system (physician-assisted telemedicine)
Number of subjects: 696
Study 29674306 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABEO telemedicine system (nurse-assisted telemonitoring and teleconsultations)
Number of subjects: 696
Study 29674306 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up (control group)
Number of subjects: 696
Study 29674323 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) for up to 7 days in CF participants
Number of subjects: 0
Study 29674323 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (HCs)
Number of subjects: 0
Study 29674365 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 compressions and 2 s pause
Number of subjects: 552
Study 29674365 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 compressions and 5 s pause
Number of subjects: 552
Study 29674365 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 compressions and 10 s pause
Number of subjects: 552
Study 29674365 — intervention group
Group type: COMPARATOR
Intervention: hands-only CPR
Number of subjects: 552
Study 29674506 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs (specifically miR-126-5p)
Number of subjects: 141
Study 29674506 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 141
Study 29674852 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive trans-iliac sacroiliac joint fusion using triangular titanium implants (TTI)
Number of subjects: 103
Study 29675856 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE, 1 μm) combined with carbachol (CA, 3 μm)
Number of subjects: 28
Study 29675856 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC inhibitor GF 109203X
Number of subjects: 28
Study 29675856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rho kinase inhibitor Y-27632
Number of subjects: 28
Study 29675856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of PKC inhibitor and Rho kinase inhibitor
Number of subjects: 28
Study 29676033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29676049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced moderate weight loss (5% weight loss)
Number of subjects: 11
Study 29676557 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 364
Study 29676557 — intervention group
Group type: COMPARATOR
Intervention: Practice-based collaborative care
Number of subjects: 364
Study 29677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged and exclusive breastfeeding promotion modelled on the Baby-Friendly Hospital Initiative
Number of subjects: 13557
Study 29677187 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for ≥3 months
Number of subjects: 13557
Study 29677187 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 13557
Study 29677353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal delivery (1 × 10^12 vg)
Number of subjects: 22
Study 29677353 — intervention group
Group type: COMPARATOR
Intervention: Subretinal delivery (1 × 10^10 vg)
Number of subjects: 22
Study 29677353 — intervention group
Group type: COMPARATOR
Intervention: Subretinal delivery (high dose: 1 × 10^12 vg)
Number of subjects: 22
Study 29677353 — intervention group
Group type: COMPARATOR
Intervention: Subretinal delivery (low dose: 1 × 10^11 vg)
Number of subjects: 22
Study 29677606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 40
Study 29678146 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant S-1 chemotherapy
Number of subjects: 375
Study 29678146 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 375
Study 29678146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy including S-1 (IS)
Number of subjects: 375
Study 29678146 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy not including S-1 (NIS)
Number of subjects: 375
Study 29678145 — intervention group
Group type: EXPERIMENTAL
Intervention: PET and staging laparoscopy (SL)
Number of subjects: 543
Study 29678183 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio diet based on several food items with suggested anti-inflammatory effects
Number of subjects: 50
Study 29678183 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study 29678204 — intervention group
Group type: COMPARATOR
Intervention: Low pressure irrigation
Number of subjects: 2447
Study 29678204 — intervention group
Group type: COMPARATOR
Intervention: Soap treatment
Number of subjects: 2447
Study 29678409 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy for neonatal hyperbilirubinemia
Number of subjects: 135
Study 29678409 — intervention group
Group type: COMPARATOR
Intervention: No phototherapy
Number of subjects: 135
Study 29678476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Lapatinib (intravenous cabazitaxel 20 mg/m²)
Number of subjects: 11
Study 29678669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogeriatric consultation
Number of subjects: 31
Study 29678669 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric screening
Number of subjects: 31
Study 29678669 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation report
Number of subjects: 31
Study 29678802 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call enrollment
Number of subjects: 719
Study 29678802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat/Instant Message (IM) enrollment
Number of subjects: 719
Study 29678802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated enrollment process
Number of subjects: 719
Study 29678802 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall enrollment process modifications
Number of subjects: 719
Study 29678802 — intervention group
Group type: COMPARATOR
Intervention: Automated process vs. phone interaction
Number of subjects: 719
Study 29678801 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma prevalence
Number of subjects: 380
Study 29678801 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma association with glycemic control
Number of subjects: 380
Study 29678804 — intervention group
Group type: EXPERIMENTAL
Intervention: iWaWa treatment (8 weeks)
Number of subjects: 89
Study 29678804 — intervention group
Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 89
Study 29678813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB) documented in 1357 patients (20.0%) with an incidence rate of 14.8 events per 100 person-years.
Number of subjects: 6771
Study 29678813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuisance bleeding (NB)
Number of subjects: 6771
Study 29678971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified intervention (StepSmart Challenge) involving a pedometer competition and material rewards
Number of subjects: 19